Primary outcome: partial clinical response · patients with cutaneous disease in systemic lupus erythematosus
Oral hydroxychloroquine showed no clear difference in primary outcome: partial clinical response compared with placebo (low certainty).
1 finding from 1 review
Adherence · participants with recurrent herpes labialis
1 finding from 1 review
Incidence of herpes labialis during use of the preventative intervention · participants with recurrent herpes labialis
2 findings from 1 review
Duration of attack of herpes labialis during use of the preventative intervention · participants with recurrent herpes labialis
1 finding from 1 review
Complete response · patients with cutaneous disease in systemic lupus erythematosus
Oral dehydroepiandrosterone showed no clear difference in primary outcome: complete clinical response compared with placebo (moderate certainty).
1 finding from 1 review
Primary outcome: partial clinical response · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Secondary outcome: clinical flare · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Secondary outcome: CLASI · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Secondary outcome: Dermatology Quality of Life measure · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus
Oral dehydroepiandrosterone showed no clear difference in adverse events: severe compared with placebo (moderate certainty).
1 finding from 1 review
Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus
Oral dehydroepiandrosterone probably leads to higher adverse events: minor compared with placebo (moderate certainty).
1 finding from 1 review
Incidence of herpes labialis after use of the preventative intervention · participants with recurrent herpes labialis
Oral aciclovir (short‐term) showed no clear difference in incidence of herpes labialis during use of the preventative… compared with placebo (moderate certainty).
1 finding from 1 review
Incidence of herpes labialis during use of the preventative intervention · participants with recurrent herpes labialis
Oral aciclovir (short‐term) may leads to lower incidence of herpes labialis during use of the preventative… compared with placebo (low certainty).
1 finding from 1 review
Incidence of herpes labialis during use of the preventative intervention (by clinical evaluation) ‐ aciclovir 200 mg 5 times/day · participants with recurrent herpes labialis
Oral aciclovir (short‐term) showed no clear difference in incidence of herpes labialis during use of the preventative… compared with placebo (low certainty).
1 finding from 1 review
Incidence of herpes labialis during use of the preventative intervention (by culture) ‐ aciclovir 400 mg twice daily · participants with recurrent herpes labialis
Oral aciclovir (short‐term) may leads to lower incidence of herpes labialis during use of the preventative… compared with placebo (low certainty).
1 finding from 1 review
Adverse effects during use of the preventative intervention ‐ aciclovir 800 mg twice daily · participants with recurrent herpes labialis
Oral aciclovir (short‐term) showed no clear difference in adverse effects during use of the preventative intervention ‐… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects during use of the preventative intervention ‐ aciclovir 400 mg twice daily · participants with recurrent herpes labialis
Oral aciclovir (short‐term) showed no clear difference in adverse effects during use of the preventative intervention ‐… compared with placebo (low certainty).
1 finding from 1 review
Primary: investigator‐rated good/excellent control of symptoms · people with moderate to severe chronic hand eczema
Oral retinoids: alitretinoin 30 mg leads to higher primary: investigator‐rated good/excellent control of symptoms compared with placebo (high certainty).
1 finding from 1 review
Primary: participant‐rated good/excellent control of symptoms · people with moderate to severe chronic hand eczema
Oral retinoids: alitretinoin 30 mg leads to higher primary: participant‐rated good/excellent control of symptoms… compared with placebo (high certainty).
1 finding from 1 review
Adverse effects: headache · people with moderate to severe chronic hand eczema
Oral retinoids: alitretinoin 30 mg leads to higher primary: adverse events ‐ headache Folluw‐up: 48 weeks to 72 weeks compared with placebo (high certainty).
1 finding from 1 review